Project 1 will use in vitro and in vivo models to investigate signal transduction pathways that transduce activation of mixed lineage kinase type 3 (MLKS), because we hypothesize that pathologic activation of MLKS leads to neuroinflammation and loss of synaptic plasticity in HAND. Using 2nd generation small molecule MLK3 inhibitors (designated as our lead compound URMC-099 or their descendant congeners, URMC-099c*) developed by our industry partner, Califia Bio Inc in Project 2, we have demonstrated that URMC-099 blocks pro-inflammatory cytokine production from HIV-1 Tat-stimulated monocyte-derived macrophage and microglia in vitro, as well as prevents leukocyte trafficking in CNS vasculature and damage to synaptic architecture following stereotactic injection of Tat in the CNS in vivo. Additionally, we have demonstrated that MLKS inhibition with these inhibitors increases the neuronal Tri

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
5P01MH064570-10
Application #
8279402
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
10
Fiscal Year
2011
Total Cost
$444,926
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Olson, Katherine E; Bade, Aditya N; Namminga, Krista L et al. (2018) Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. J Neurovirol 24:398-410
Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26
Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443
Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154
Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137
Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65
Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev :

Showing the most recent 10 out of 203 publications